Product How it works Pricing Blog FAQ About Contact
Español English
EspañolEnglish
Log inCreate free account
Palisade Bio

Palisade Bio (NASDAQ: PALI) insider transactions

In the twelve months to 10 November 2026, executives and directors of Palisade Bio reported 4 open-market sales of 204,563 shares ($420,525) and 10 open-market purchases of 155,000 shares ($296,650), by 4 people, according to the Form 4 filings they submitted to the SEC.

Latest transactions

The 20 most recent transactions in Palisade Bio shares reported on Form 4
DateInsiderRoleTransactionSharesPriceHeld afterFiling
19 October 2026Capers Julien E.See RemarksGrant or award+787,300—787,300Form 4
6 October 2026Finley John DavidCEO CFOOption exercise+3,227,384—3,356,672Form 4
6 October 2026Finley John DavidCEO CFOShares withheld for tax−1,411,982$1.491,944,690Form 4
6 October 2026Jones Mitchell LawrenceSee RemarksOption exercise+2,620,850—2,714,859Form 4
6 October 2026Jones Mitchell LawrenceSee RemarksShares withheld for tax−1,031,102$1.491,683,757Form 4
2 October 2026Williams Donald AllenDirectorOpen-market purchase+10,000$1.461,590,294Form 4
1 October 2026Williams Donald AllenDirectorOpen-market purchase+10,000$1.421,580,294Form 4
19 August 2026Finley John DavidCEO, CFOGift−88,400—129,288Form 4
19 August 2026Finley John DavidCEO, CFOGift+88,400—88,451Form 4
9 July 2026Baltera Robert Jr.DirectorOpen-market purchase+25,000$1.96461,904Form 4
8 July 2026Baltera Robert Jr.DirectorOpen-market purchase+20,000$1.99436,904Form 4
7 July 2026Finley John DavidCEO, CFOOpen-market sale−146,798$2.07217,555Form 4
7 July 2026Finley John DavidCEO, CFOOption exercise+133$0.70217,688Form 4
7 July 2026Jones Mitchell LawrenceChief Medical OfficerOpen-market sale−51,880$2.0594,009Form 4
7 July 2026Baltera Robert Jr.DirectorOpen-market purchase+30,000$2.03416,904Form 4
6 July 2026Finley John DavidCEO, CFOOption exercise+335,167—364,353Form 4
6 July 2026Jones Mitchell LawrenceChief Medical OfficerOption exercise+131,167—145,889Form 4
6 July 2026Baltera Robert Jr.DirectorOpen-market purchase+20,000$2.05386,904Form 4
2 July 2026Baltera Robert Jr.DirectorOpen-market purchase+10,000$1.98366,904Form 4
1 July 2026Baltera Robert Jr.DirectorOpen-market purchase+20,000$1.98356,904Form 4

Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.

How to read the table

Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.

Where each row comes from

From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Palisade Bio page; the method, in data sources.

Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.